NCT05482893
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05482893
Title Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Phanes Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope (City of Hope National Medical Center, City of Hope Medical Center) RECRUITING Duarte California 91010 United States Details
USC Norris Comprehensive Cancer Center RECRUITING Los Angeles California 90033 United States Details
Sarah Cannon Research Institute (SCRI) RECRUITING Denver Colorado 80218 United States Details
University of Iowa RECRUITING Iowa City Iowa 52242 United States Details
Norton Cancer Institute RECRUITING Louisville Kentucky 40202 United States Details
Dana-Farber Cancer Institute (DFCI) ACTIVE_NOT_RECRUITING Boston Massachusetts 02215 United States Details
Duke Cancer Center RECRUITING Durham North Carolina 27710 United States Details
University of Pittsburgh Medical Center (UPMC) RECRUITING Pittsburgh Pennsylvania 15232 United States Details
MD Anderson Cancer Center, GI Medical Oncology Dept RECRUITING Houston Texas 77030 United States Details
NEXT Oncology RECRUITING Fairfax Virginia 22031 United States Details
University of Wisconsin Carbone Cancer Center - University Hospital RECRUITING Madison Wisconsin 53792 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field